Bristol-Myers Squibb (NYSE:BMY) announced positive results from the Phase 3 POETYK PsA-1 trial of Sotyktu, showcasing its ...

Under this deal, Philochem will grant RayzeBio exclusive worldwide rights to develop, manufacture, and market OncoACP3, a ...

Study reveals the advantages and pitfalls of adding a TKI to a monoclonal antibody after chemoradiation for non-small cell ...

Sildenafil citrate during labor did not improve perinatal outcomes potentially related to intrapartum hypoxia despite ...

We recently published a list of Was Jim Cramer Right About These 9 Stocks? In this article, we are going to take a look at ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Goldman Sachs 46th Annual Global Healthcare Conference June 11, 2025 10:00 AM ETCompany ParticipantsAdam Lenkowsky ...

The Florida State University community mourns the loss of esteemed chemist and noted inventor Robert Holton, whose ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

BMS entered the radiopharma space via its $4.1 billion buyout of RayzeBio at the end of 2023. Unlike Novartis’ approved ...

OncoACP3 is a small molecule ligand with high affinity and specificity for Acid Phosphatase 3 (ACP3), a novel target in ...

Nine years after selling Medivation to Pfizer for $14 billion, David Hung, M.D., is going toe to toe with the New York ...